West Pharmaceutical Services (WST) Common Equity (2009 - 2026)

West Pharmaceutical Services has disclosed Common Equity across 18 years of filings, most recently posting $3.0 billion for Q2 2026.

• In Q2 2026, Common Equity rose 2.09% year-over-year to $3.0 billion; the TTM figure through Jun 2026 stood at $3.0 billion (up 2.09% YoY), while the FY2025 annual figure was $3.2 billion, up 18.41% from the prior year.
• Common Equity came in at $3.0 billion for Q2 2026 at West Pharmaceutical Services, roughly flat from $3.0 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $3.2 billion in Q4 2025 to a low of $2.3 billion in Q1 2022.
• Average Common Equity over 5 years is $2.8 billion, with a median of $2.7 billion recorded in 2023.
• Year-over-year, Common Equity climbed 27.18% in 2022 and fell 6.9% in 2024.
• Over 5 years, Common Equity stood at $2.7 billion in 2022, then climbed by 7.3% to $2.9 billion in 2023, then declined by 6.9% to $2.7 billion in 2024, then rose by 18.41% to $3.2 billion in 2025, then decreased by 5.85% to $3.0 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $3.0 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.2 billion in Q4 2025.